{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:18:16Z","timestamp":1769498296328,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24398-6","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:02:27Z","timestamp":1763553747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0032-194X","authenticated-orcid":false,"given":"Maximilian Cosma","family":"Gliga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3013-490X","authenticated-orcid":false,"given":"Laura","family":"Chinezu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Preda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Ilie","family":"Rotariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-1379","authenticated-orcid":false,"given":"Maria Ionela","family":"Pascanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"1","key":"24398_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu, M. et al. A pituitary society update to acromegaly management guidelines. Pituitary 24 (1), 1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7 (2021).","journal-title":"Pituitary"},{"issue":"1","key":"24398_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa, S. L., Mete, O., Perry, A. & Osamura, R. Y. Overview of the 2022 WHO classification of pituitary tumors. Endocr. Pathol. 33 (1), 6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7 (2022).","journal-title":"Endocr. Pathol."},{"issue":"6","key":"24398_CR3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1210\/clinem\/dgab069","volume":"106","author":"EC Coopmans","year":"2021","unstructured":"Coopmans, E. C. et al. Predictors for remission after transsphenoidal surgery in acromegaly: A Dutch multicenter study. J. Clin. Endocrinol. Metab. 106 (6), 1783\u20131792. https:\/\/doi.org\/10.1210\/clinem\/dgab069 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"24398_CR4","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson, L. et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99 (11), 3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"24398_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-10-0586","volume":"163","author":"Y Bakhtiar","year":"2010","unstructured":"Bakhtiar, Y. et al. Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163 (4), 531\u2013539. https:\/\/doi.org\/10.1530\/EJE-10-0586 (2010).","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"24398_CR6","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1111\/jcmm.16173","volume":"25","author":"J Soukup","year":"2021","unstructured":"Soukup, J. et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. J. Cell. Mol. Med. 25 (5), 2484\u20132492. https:\/\/doi.org\/10.1111\/jcmm.16173 (2021).","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"24398_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00701-014-2230-6","volume":"156","author":"S Sarkar","year":"2014","unstructured":"Sarkar, S., Chacko, A. G. & Chacko, G. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir. (Wien). 156 (12), 2221\u20132230. https:\/\/doi.org\/10.1007\/s00701-014-2230-6 (2014).","journal-title":"Acta Neurochir. (Wien)"},{"issue":"2","key":"24398_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-13-0349","volume":"169","author":"L Kasuki","year":"2013","unstructured":"Kasuki, L. et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur. J. Endocrinol. 169 (2), 217\u2013223. https:\/\/doi.org\/10.1530\/EJE-13-0349 (2013).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"24398_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha, M. R., Wildemberg, L. E. & Kasuki, L. The future of somatostatin receptor ligands in acromegaly. J. Clin. Endocrinol. Metab. 107 (2), 297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"24398_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.47162\/RJME.61.2.05","volume":"61","author":"N Ionovici","year":"2020","unstructured":"Ionovici, N. et al. Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report \u2013 a review. Rom. J. Morphol. Embryol. 61 (2), 353\u2013359. https:\/\/doi.org\/10.47162\/RJME.61.2.05 (2020).","journal-title":"Rom. J. Morphol. Embryol."},{"issue":"1","key":"24398_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.humpath.2013.08.007","volume":"45","author":"L Chinezu","year":"2014","unstructured":"Chinezu, L. et al. Expression of somatostatin receptors, SSTR2A and SSTR 5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum. Pathol. 45 (1), 71\u201377. https:\/\/doi.org\/10.1016\/j.humpath.2013.08.007 (2014).","journal-title":"Hum. Pathol."},{"key":"24398_CR12","doi-asserted-by":"publisher","unstructured":"Peverelli, E. et al. Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement. Front. Endocrinol. (Lausanne). 6 (DEC). https:\/\/doi.org\/10.3389\/fendo.2015.00187 (2015).","DOI":"10.3389\/fendo.2015.00187"},{"key":"24398_CR13","doi-asserted-by":"publisher","unstructured":"Luo, M., Yu, J. & Tang, R. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in acromegaly. J Neurooncol Published online 2024. https:\/\/doi.org\/10.1007\/s11060-024-04620-7","DOI":"10.1007\/s11060-024-04620-7"},{"issue":"9","key":"24398_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41574-021-00514-0","volume":"17","author":"E Peverelli","year":"2021","unstructured":"Peverelli, E. et al. Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. Nat. Rev. Endocrinol. 17 (9), 560\u2013571. https:\/\/doi.org\/10.1038\/s41574-021-00514-0 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"24398_CR15","doi-asserted-by":"publisher","unstructured":"Zhou, J., Kang, X., An, H., Lv, Y. & Liu, X. The function and pathogenic mechanism of filamin A. Gene 784 https:\/\/doi.org\/10.1016\/j.gene.2021.145575 (2021).","DOI":"10.1016\/j.gene.2021.145575"},{"issue":"1","key":"24398_CR16","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/eo-22-0055","volume":"2","author":"D Treppiedi","year":"2022","unstructured":"Treppiedi, D., Catalano, R., Mangili, F., Mantovani, G. & Peverelli, E. Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. Endocr. Oncol. 2 (1), R143\u2013R152. https:\/\/doi.org\/10.1530\/eo-22-0055 (2022).","journal-title":"Endocr. Oncol."},{"key":"24398_CR17","doi-asserted-by":"publisher","unstructured":"Savoy, R. M. & Ghosh, P. M. The dual role of filamin A in cancer: can\u2019t live with (too much of) it, can\u2019t live without it. Endocr. Relat. Cancer. 20 (6). https:\/\/doi.org\/10.1530\/ERC-13-0364 (2013).","DOI":"10.1530\/ERC-13-0364"},{"issue":"12","key":"24398_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1055\/s-0034-1384520","volume":"46","author":"E Peverelli","year":"2014","unstructured":"Peverelli, E. et al. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP\/PKA dependent phosphorylation. Horm. Metab. Res. 46 (12), 845\u2013853. https:\/\/doi.org\/10.1055\/s-0034-1384520 (2014).","journal-title":"Horm. Metab. Res."},{"key":"24398_CR19","doi-asserted-by":"publisher","unstructured":"Mangili, F. et al. A novel mechanism regulating dopamine receptor type 2 signal transduction in pituitary tumoral cells: the role of cAMP\/PKA-Induced filamin A phosphorylation. Front. Endocrinol. (Lausanne). 11 https:\/\/doi.org\/10.3389\/fendo.2020.611752 (2021).","DOI":"10.3389\/fendo.2020.611752"},{"issue":"2","key":"24398_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11102-019-00947-x","volume":"22","author":"T Sickler","year":"2019","unstructured":"Sickler, T. et al. Filamin A and DRD2 expression in corticotrophinomas. Pituitary 22 (2), 163\u2013169. https:\/\/doi.org\/10.1007\/s11102-019-00947-x (2019).","journal-title":"Pituitary"},{"key":"24398_CR21","doi-asserted-by":"publisher","unstructured":"Coelho, M. C. A. et al. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Sci. Rep. 9 (1). https:\/\/doi.org\/10.1038\/s41598-018-37692-3 (2019).","DOI":"10.1038\/s41598-018-37692-3"},{"issue":"8","key":"24398_CR22","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1210\/en.2014-1063","volume":"155","author":"E Peverelli","year":"2014","unstructured":"Peverelli, E. et al. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology 155 (8), 2932\u20132941. https:\/\/doi.org\/10.1210\/en.2014-1063 (2014).","journal-title":"Endocrinology"},{"key":"24398_CR23","doi-asserted-by":"publisher","unstructured":"Treppiedi, D. et al. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. Mol. Cell. Endocrinol. 524 https:\/\/doi.org\/10.1016\/j.mce.2021.111159 (2021).","DOI":"10.1016\/j.mce.2021.111159"},{"key":"24398_CR24","unstructured":"Romanian National Health Insurance House (CNAS). Therapeutic protocol for acromegaly and gigantism. Available at: https:\/\/cnas.ro\/wp-content\/uploads\/2024\/03\/protocoale.pdf (Accessed: 05.01.2025)."},{"issue":"3","key":"24398_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11102-018-0884-4","volume":"21","author":"MJ van Esdonk","year":"2018","unstructured":"van Esdonk, M. J. et al. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary 21 (3), 310\u2013322. https:\/\/doi.org\/10.1007\/s11102-018-0884-4 (2018).","journal-title":"Pituitary"},{"issue":"16","key":"24398_CR26","doi-asserted-by":"publisher","first-page":"8663","DOI":"10.3390\/ijms25168663","volume":"25","author":"MC Gliga","year":"2024","unstructured":"Gliga, M. C., Chinezu, L. & Pascanu, I. M. Predicting response to medical treatment in acromegaly via granulation Pattern, expression of somatostatin receptors type 2 and 5 and E-Cadherin. Int. J. Mol. Sci. 25 (16), 8663. https:\/\/doi.org\/10.3390\/ijms25168663 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"24398_CR27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1210\/jc.2011-2902","volume":"97","author":"E Peverelli","year":"2012","unstructured":"Peverelli, E. et al. Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. J. Clin. Endocrinol. Metab. 97 (3), 967\u2013977. https:\/\/doi.org\/10.1210\/jc.2011-2902 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"24398_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7150\/ijbs.5577","volume":"9","author":"X Jiang","year":"2012","unstructured":"Jiang, X. et al. Inhibition of filamin-A reduces cancer metastatic potential. Int. J. Biol. Sci. 9 (1), 67\u201377. https:\/\/doi.org\/10.7150\/ijbs.5577 (2012).","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"24398_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12253-015-9980-1","volume":"22","author":"QQ Shao","year":"2016","unstructured":"Shao, Q. Q. et al. Filamin A: insights into its exact role in cancers. Pathol. Oncol. Res. 22 (2), 245\u2013252. https:\/\/doi.org\/10.1007\/s12253-015-9980-1 (2016).","journal-title":"Pathol. Oncol. Res."},{"key":"24398_CR30","doi-asserted-by":"publisher","unstructured":"Toledo, J. et al. FLNA expression modulates pathological markers of pituitary neuroendocrine tumours. J. Endocrinol. 260 (1). https:\/\/doi.org\/10.1530\/JOE-23-0209 (2024).","DOI":"10.1530\/JOE-23-0209"},{"issue":"1","key":"24398_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","volume":"20","author":"A Lavrentaki","year":"2017","unstructured":"Lavrentaki, A., Paluzzi, A., Wass, J. A. H. & Karavitaki, N. Epidemiology of acromegaly: review of population studies. Pituitary 20 (1), 4\u20139. https:\/\/doi.org\/10.1007\/s11102-016-0754-x (2017).","journal-title":"Pituitary"},{"issue":"6","key":"24398_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito, D., Ragnarsson, O., Johannsson, G. & Olsson, D. S. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur. J. Endocrinol. 182 (6), 523\u2013531. https:\/\/doi.org\/10.1530\/EJE-20-0019 (2020).","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"24398_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5603\/EP.a2017.0041","volume":"68","author":"DA Niculescu","year":"2017","unstructured":"Niculescu, D. A. et al. Acromegaly treatment in Romania. How close are we to disease control? Endokrynol Pol. 68 (5), 519\u2013523. https:\/\/doi.org\/10.5603\/EP.a2017.0041 (2017).","journal-title":"Endokrynol Pol."},{"issue":"3","key":"24398_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5603\/EP.a2020.0020","volume":"71","author":"MC Marinescu","year":"2020","unstructured":"Marinescu, M. C. et al. Improvement of acromegaly control with multimodal therapy in Romania. Endokrynol Pol. 71 (3), 235\u2013239. https:\/\/doi.org\/10.5603\/EP.a2020.0020 (2020).","journal-title":"Endokrynol Pol."},{"issue":"10","key":"24398_CR35","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00701-023-05772-7","volume":"165","author":"CM Falch","year":"2023","unstructured":"Falch, C. M. et al. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir. (Wien). 165 (10), 3003\u20133010. https:\/\/doi.org\/10.1007\/s00701-023-05772-7 (2023).","journal-title":"Acta Neurochir. (Wien)"},{"issue":"3","key":"24398_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1530\/EJE-21-0729","volume":"186","author":"S Arnard\u00f3ttir","year":"2022","unstructured":"Arnard\u00f3ttir, S. et al. Long-term outcomes of patients with acromegaly: a report from the Swedish pituitary register. Eur. J. Endocrinol. 186 (3), 329\u2013339. https:\/\/doi.org\/10.1530\/EJE-21-0729 (2022).","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"24398_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.47162\/RJME.64.1.03","volume":"64","author":"MC Gliga","year":"2023","unstructured":"Gliga, M. C., T\u0103t\u0103ranu, L. G., Popescu, M., Chinezu, L. & Pa\u015fcanu, M. I. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review. Rom. J. Morphol. Embryol. 64 (1), 25\u201333. https:\/\/doi.org\/10.47162\/RJME.64.1.03 (2023).","journal-title":"Rom. J. Morphol. Embryol."},{"key":"24398_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canlet.2018.08.002","volume":"435","author":"E Peverelli","year":"2018","unstructured":"Peverelli, E. et al. cAMP\/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells. Cancer Lett. 435, 101\u2013109. https:\/\/doi.org\/10.1016\/j.canlet.2018.08.002 (2018).","journal-title":"Cancer Lett."},{"issue":"3","key":"24398_CR39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","volume":"23","author":"M Bolanowski","year":"2022","unstructured":"Bolanowski, M., Ka\u0142u\u017cny, M., Witek, P. & Jawiarczyk-Przyby\u0142owska, A. Pasireotide\u2014a novel somatostatin receptor ligand after 20 years of use. Rev. Endocr. Metab. Disord. 23 (3), 601\u2013620. https:\/\/doi.org\/10.1007\/s11154-022-09710-3 (2022).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"24398_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/DDDT.S77999","volume":"10","author":"D Cuevas-Ramos","year":"2016","unstructured":"Cuevas-Ramos, D., Fleseriu, M. & Pasireotide A novel treatment for patients with acromegaly. Drug Des. Devel Ther. 10, 227\u2013239. https:\/\/doi.org\/10.2147\/DDDT.S77999 (2016).","journal-title":"Drug Des. Devel Ther."},{"issue":"2","key":"24398_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo, D. et al. Factors predicting Pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174 (2), 241\u2013250. https:\/\/doi.org\/10.1530\/EJE-15-0832 (2016).","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"24398_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle, H. et al. Pasireotide-LAR in acromegaly patients treated with a combination therapy: A real-life study. Endocr. Connect. 8 (10), 1383\u20131394. https:\/\/doi.org\/10.1530\/EC-19-0332 (2019).","journal-title":"Endocr. Connect."},{"key":"24398_CR43","doi-asserted-by":"publisher","unstructured":"Puig-Domingo, M. et al. Pasireotide in the personalized treatment of acromegaly. Front. Endocrinol. (Lausanne). 12 https:\/\/doi.org\/10.3389\/fendo.2021.648411 (2021).","DOI":"10.3389\/fendo.2021.648411"}],"updated-by":[{"DOI":"10.1038\/s41598-026-36974-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24398-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T09:02:02Z","timestamp":1769418122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24398-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24398"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24398-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-36974-5","URL":"https:\/\/doi.org\/10.1038\/s41598-026-36974-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the The Scientific-Research Ethics Committee of George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mures. Informed consent was obtained from all participating subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"40706"}}